Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-099115
Filing Date
2024-08-20
Accepted
2024-08-20 16:24:17
Documents
106
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 20-F vrax-20240331.htm   iXBRL 20-F 3282494
2 EX-8.1 vrax-ex8_1.htm EX-8.1 13191
3 EX-12.1 vrax-ex12_1.htm EX-12.1 8978
4 EX-12.2 vrax-ex12_2.htm EX-12.2 8366
5 EX-13.1 vrax-ex13_1.htm EX-13.1 7131
6 EX-13.2 vrax-ex13_2.htm EX-13.2 7132
7 GRAPHIC img134772027_0.jpg GRAPHIC 70337
8 GRAPHIC img134772027_1.jpg GRAPHIC 5643
  Complete submission text file 0000950170-24-099115.txt   13085989

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vrax-20240331.xsd EX-101.SCH 1809064
108 EXTRACTED XBRL INSTANCE DOCUMENT vrax-20240331_htm.xml XML 2600861
Mailing Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH
Business Address BIOCITY GLASGOW BO'NESS ROAD, NEWHOUSE LANARKSHIRE X0 ML1 5UH 44 020 7788 7414
Virax Biolabs Group Ltd (Filer) CIK: 0001885827 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0331
Type: 20-F | Act: 34 | File No.: 001-41440 | Film No.: 241225470
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)